. 13 C NMR-APT CDCl3, 50 MHz) of 1-phenylbut-3-en-1-ol. 13 C NMR (50 MHz, CDCl 3 ): δ= 144. 57, 135.18, 129.09, 128.22, 126.54, 119.02, 74.03, 44 .49 IR (cm -1 ): 3371, 3070, 3028, 2904, 1639, 1492, 1049, 995, 914, 756, 702. Figure S4 . NMR 13 C-APT (CDCl3, 50 MHz) of 1-(4-fluorophenyl)but-3-en-1-ol. 13 C NMR (50 MHz, CDCl 3 ): δ= 165. 29, 160.42, 140.31, 140.25, 134.96, 134.88, 128.29, 128.13, 119.36, 116.13, 115.71, 73.45, 73.33, 44.62 . -10  0  10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170  180  190  200  210  220 f1 ( Figure S7 . 13 C NMR-APT (CDCl3, 50 MHz) of 1-(naphthalen-2-yl)but-3-en-1-ol.
IR (cm -1 ): 3383, 3078, 2981, 2908, 1604, 11508, 1049, 995, 914, 837. 13 C NMR (50 MHz, CDCl 3 ) δ 141. 98, 135.11, 133.98, 133.67, 128.94, 128.70, 128.42, 126.86, 126.55, 125.26, 124.75, 119.23, 74.19 Figure S12 . NOSY of 2,6-diphenyl-tetrahydro-2H-pyran-4-ol (1a). Figure S14 . 13 C NMR-APT (CDCl3, 50 MHz) of 2,6-di(naphthalen-2-yl)-tetrahydro-2H-pyran-4-ol (1b).
13 C NMR (50 MHz, CDCl 3 ): δ= 165. 36, 160.48, 138.39, 138.33, 128.41, 128.25, 116.18, 115.75, 78.14, 78.06, 69.09, 43.70 . IR (cm -1 ): 3329, 3051, 2943, 2854, 1604, 1512, 1230, 1068, 821. 13 C NMR (125 MHz, DMSO): δ= 140. 76, 133.40, 132.94, 128.41, 128.30, 128.02, 126.59, 126.28, 125.08, 124.64, 77.81, 67.35, 43.63 IR (cm -1 ): 3032, 2970, 2858, 1720, 1604, 1496, 1056, 1060, 752, 698 . 25, 165.65, 160.74, 137.14, 137.08, 128.28, 128.12, 116.54, 116.11, 79.12, 50 IR (cm -1 ): 3348, 3309, 3155, 3062, 3035, 2862, 1674, 1597, 1627, 1492, 1064, 756, 698. 13 C NMR (50 MHz, CD 3 OD): δ= 167. 43, 162.56, 159.86, 157.84, 140.17, 130.29, 117.19, 81.64, 44.65, 38.24 . IR (cm -1 ): 3390, 3352, 3271, 3066, 2958, 2850, 1670, 1604, 1627, 1508, 1080, 825 . 13 C NMR (50 MHz, CD 3 OD): δ= 158. 98, 158.34, 141.44, 135.97, 135.83, 130.43, 130.04, 128.55, 128.41, 127.13, 126.90, 126.35, 82.24, 0, 44.49, 38.26 . 35  40  45  50  55  60  65  70  75  80  85  90  95  100  105  110  115  120  125  130  135  140  145  150  155  160  165 f1 ( IR (cm -1 ): 3423, 3340, 3155, 3055, 1672, 1600, 1625, 1508, 1078, 817, 748. 13 C NMR (50 MHz, CD 3 OD): δ= 161. 81, 159.32, 158.24, 145.58, 145.09, 144.08, 143.32, 130.76, 130.54, 128.19, 82.02, 80.46, 44.71, 42.66, 40.69, 38.21 IR (cm -1 ): 3568, 3448, 3062, 3032, 2862, 1674, 1631, 1631, 1492, 1126, 1064, 756, 698 . 13 C NMR (50 MHz, CD 3 OD): δ= 168. 48, 163.63, 159.25, 142.88, 142.82, 142.44, 142.38, 131.49, 118.63, 118.21, 81.27, 77.61, 41.92, 39.37 Figure S44 . IR (KBr, cm −1 ) of 2-((cis,trans)-2,6-bis(4-fluorophenyl)tetrahydro-2H-pyran-4-yl)hydrazinecarboximidamide hydrochloride (6). Figure S45 . 13 C NMR-APT (CD3OD, 50 MHz) of 2-((cis,trans)-2,6-di(naphthalen-2-yl)tetrahydro-2H-pyran-4-yl)hydrazinecarboximidamide hydrochloride (7).
13 C NMR (50 MHz, CD 3 OD): δ = 163. 17, 160.56, 159.60, 144.35, 143.83, 142.76, 142.04, 137.29, 137.14, 136.96, 131.64, 131.58, 131.23, 129.78, 129.66, 129.40, 128.47, 128.40, 128.20, 128.01, 127.93, 127.67, 83.64, 82.10, 78.42, 60.92, , 45 .87, IR (cm −1 ): 3568, 3452, 2924, 2870, 1666, 1639, 1639, 1512, 1126, 1076, Figure S48 . Effects of compound 3 in K562 cell cycle distribution, after 24 h. Cell cycle analysis was quantified by Flow cytometer on FL2-A, 10,000 events were recorded in each experiment. Data are expressed as percentage values. Each result was performed in duplicate, and data are reported as mean ± SD of at least three independent experiments. *P < 0.05; **<0.01; ***P < 0.001 vs control group. Figure S49 . Effects of compound 7 in K562 cell cycle distribution, after 24 hours. Cell cycle analysis was quantified by Flow cytometer on FL2-A, 10000 events were recorded in each experiment. Data are expressed as percentage values. Each result was performed in duplicate, and data are reported as mean ± SD of at least three independent experiments. *P < 0.05; **<0.01; ***P < 0.001 vs control group.
